Journal article
Pharmacokinetic properties of conventional and double-dose sulfadoxine-pyrimethamine given as intermittent preventive treatment in infancy
S Salman, S Griffin, K Kose, N Pitus, J Winmai, B Moore, P Siba, KF Ilett, I Mueller, TME Davis
Antimicrobial Agents and Chemotherapy | AMER SOC MICROBIOLOGY | Published : 2011
DOI: 10.1128/AAC.01075-10
Abstract
Intermittent preventive treatment in infancy (IPTi) entails routine administration of antimalarial treatment doses at specified times in at-risk infants. Sulfadoxine-pyrimethamine (SDX/PYR) is a combination that has been used as first-line IPTi. Because of limited pharmacokinetic data and suggestions that higher milligram/kilogram pediatric doses than recommended should be considered, we assessed SDX/PYR disposition, randomized to conventional (25/1.25 mg/kg of body weight) or double (50/2.5 mg/kg) dose, in 70 Papua New Guinean children aged 2 to 13 months. Blood samples were drawn at baseline, 28 days, and three time points randomly selected for each infant at 4 to 8 h or 2, 5, 7, 14, or 21..
View full abstractGrants
Awarded by National Health and Medical Research Council (NHMRC) of Australia
Funding Acknowledgements
The study was funded by a grant from the IPTi Consortium and utilized facilities developed with support from the National Health and Medical Research Council (NHMRC) of Australia (grant 458555). T.M.E.D. is the recipient of an NHMRC Practitioner Fellowship.